Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. ECALTA (anidulafungine)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

ECALTA (anidulafungine)

Medicine - Posted on Jun 18 2021
Active substance (DCI)
  • anidulafungine
history (4)
  • 6/2/21

    ECALTA (anidulafungine) - Candidoses pédiatriques

    Key points Favourable opinion for reimbursement only in the treatment of invasive candidiasis in non-neutropenic patients ag...
    CAV :
    54321
    icône flèche
  • 11/30/16

    ECALTA (anidulafungin), echinocandin

    Insufficient actual benefit in the treatment of invasive candidiasis in adults with neutropenia ECALTA now has Marketing Aut...
    CAV :
    54321
    icône flèche
  • 9/8/10

    ECALTA

    Pas d’avantage clinique démontré par rapport au fluconazole dans le traitement des candidoses invasives chez les adultes non...
    CAV :
    54321
    icône flèche
  • 4/16/08

    ECALTA

    ECALTA
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • J02AX06
Manufacturer
PFIZER PFE FRANCE
Presentation

ECALTA 100 mg, poudre pour solution à diluer pour perfusion (code CIS : 60614273)
1 flacon(s) en verre de 30 ml (CIP : 34009 395 983 2 1)

All our publications
    Bone marrow diseases Drug therapy Paediatrics Parasitic diseases and mycoses

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
8s2b2vp6pMCEYZpm